^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Peritoneal Cancer

    1d
    FRAPPE: Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Jul 2027 --> Jun 2028 | Trial primary completion date: Jul 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Keytruda (pembrolizumab)
    1d
    ProphyloCHIP: Trial Comparing Simple Follow-up to Exploratory Laparotomy Plus "in Principle" (Hyperthermic Intraperitoneal Chemotherapy) HIPEC in Colorectal Patients (clinicaltrials.gov)
    P3, N=150, Completed, Gustave Roussy, Cancer Campus, Grand Paris | Unknown status --> Completed
    Trial completion
    4d
    QPT-ORE-004: A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer. (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, CanariaBio Inc. | Trial completion date: Jul 2025 --> Dec 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Platinum sensitive
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Zejula (niraparib) • OvaRex (oregovomab)
    5d
    National Cancer Institute "Cancer Moonshot Biobank" (clinicaltrials.gov)
    P=N/A, N=1600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • BRCA (Breast cancer early onset)
    |
    HR positive • MSI-H/dMMR
    5d
    Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, Masonic Cancer Center, University of Minnesota | N=33 --> 3 | Trial primary completion date: Dec 2026 --> Mar 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    fludarabine IV
    5d
    BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, Brown University | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    6d
    Gastric and Rectal Administration of Encorafenib with Targeted Chemotherapy against BRAF V600E-Mutant Rectal Cancer with Bowel Obstruction. (PubMed, Oncologist)
    Targeted inhibition with the oral BRAF inhibitor encorafenib, combined with intravenous cetuximab targeting epithelial growth factor receptor (EGFR) and standard chemotherapy FOLFOX, has improved outcomes and received FDA approval in 2025 based on results from the phase III BREAKWATER trial...This case demonstrates that rectal and nasogastric administration of encorafenib is feasible, achieves therapeutic plasma concentrations, and induces objective and clinical remission in context of FOLFOX+EC. Short-term safety appeared manageable, though increased infection risk cannot be excluded.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Erbitux (cetuximab) • 5-fluorouracil • Braftovi (encorafenib) • leucovorin calcium
    6d
    FLORA-4: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (clinicaltrials.gov)
    P3, N=615, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    6d
    QPT-ORE-006: Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, CanariaBio Inc. | Trial primary completion date: Jan 2026 --> Oct 2026
    Trial primary completion date
    |
    carboplatin • paclitaxel • OvaRex (oregovomab)
    8d
    Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (clinicaltrials.gov)
    P1, N=60, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2031 --> Dec 2034 | Trial primary completion date: Dec 2030 --> Dec 2033
    Trial completion date • Trial primary completion date
    |
    BAP1 (BRCA1 Associated Protein 1)
    |
    cisplatin • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • mitomycin
    10d
    Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=111, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    metformin
    11d
    Primary Peritoneal Low-Grade Serous Carcinoma in a 16-Year-Old Female: A Case Report. (PubMed, J Clin Med)
    She completed six cycles of adjuvant chemotherapy (paclitaxel + carboplatin, TC regimen). No recurrence was observed during follow-up. This case underscores the importance of considering PPC in the differential diagnosis of pelvic masses in young females, even when the ovaries appear normal.
    Journal
    |
    MUC16 (Mucin 16, Cell Surface Associated) • PAX8 (Paired box 8)
    |
    TP53 wild-type
    |
    carboplatin • paclitaxel